Application of the Specific Imunoglobulin Therapy in The HIV Infected Persons with Chronic Toxoplasmosis


toxoplasmosis treatment
immunoglobulin against Toxoplasma Gondii

How to Cite

Hryzhak, I. H. (2015). Application of the Specific Imunoglobulin Therapy in The HIV Infected Persons with Chronic Toxoplasmosis. Galician Medical Journal, 22(4), 114-119. Retrieved from


The objective of the research was to study the effectiveness of complex treatment of HIV-infected patients with moderate chronical toxoplasmosis using azithromycin and human immunoglobulin against Toxoplasma Gondii. The patietns were not at the AIDS stage.

Materials and methods of the research. 60 patients with I, II and III clinical stage of the HIV-infection who had moderate chronic toxoplasmosis were under observation. Moderate form of toxoplasmosis was not considerated as AIDS indicator disease. The immunoenzyme method was used to determine titers of specific anti-Toxoplasma IgG and IgM, and IL-2, IL-4, IL-10, TNF-2a, IgM, IgA, IgG.

The І group of patients (30 individuals) received azithromycin inside for 21 days in a dose of 1.0 g/day, and the second group (30 persons) received azithromycin for 21 days in a dose of 1.0 g / day and human immunoglobulin against Toxoplasma Gondii every second day number 5 in a dose of 3.0 ml intramusculary.

Results. Substantial symptoms of the toxoplasmosis included swollen lymh nodes (90.0%), low-grade fever (63.33%), neurocirculatory dystonia (86.67%), moderate hepato-splenic syndrome (58.33%), weakness and fatigue (81.67%), muscle pain (36.67%), myocarditis (6.67%), chorioretinitis (3.33%).

Both groups of patients had positive clinical changes after treatment. The conditional score of toxoplasmosis activity (CSAT) was applied to illustrate the effectiveness of two treatment regimens more clearly. CSAT was the average percentage of six symptoms (fever, neurocirculatory dystonia, weakness, muscle pain, myocarditis, chorioretinitis). Before treatment CSAT constituted 46.39±6,4% and after treatment it decreased significantly to 16.67±6.8% only in patients who received azithromycin and human immunoglobulin against Toxoplasma Gondii (P<0.05).

Increased levels of IL-2, IL-4, IL-10, TNF-2a were detected in all the patients before treatment. After course of treatment with azithromycin and immunoglobulin the levels of IL-2 and TNF-2a decreased to normal in contrast to the patients who received only azithromycin.


  1. Application of the specific human immunoglobulin against Toxoplasma Gondii increased the effectiveness of treatment of moderate chronic toxoplasmosis with the use of azithromycin in the HIV-positive patients not at AIDS stage. The effectiveness of treatment manifested in the decrease in toxoplasmosis symptoms complex.
  2. The activity of proinflammatory Interleukin-2 and TNF-2a and anti-inflammatory Interleukins-4 and 10 increased in the HIV-infected persons with toxoplasmosis. After the treatment with azithromycin and human immunoglobulin against Toxoplasma Gondii the levels of IL-2 and TNF-2a decreased indicating the completion of immune inflammation process. 


Gryzhak IH, Dykyi BM, Kondryn O. [et al.] Algorithm for diagnosis of toxoplasmosis in the HIV-infected women of reproductive age and medical tactics. Profilaktychna Medytsyna. 2012; 1: 27-30.

Bodnya EI, Kotsyna SS Bobrova, OV. Toxoplasma gondii immunoglobulin against man: prospects for application in complex treatment of toxoplasmosis. Kharkiv. 2011; 64.

Bondarenko AN, Bondarenko AA. Diagnosis of toxoplasmosis in pregnant. Suchasni infektsii. 2008; 4: 11-24.

Vozianova ZHI. Infectious and parasitic diseases. Manual. Kyiv. Zdorovia. 2002; 3: 285-315.

Veselov AV, Kozlov RS. Azithromycin: modern aspects clinical of application. Klin. microbiol. antimikrob. chimiother. 2006; 8; 1: 18-32.

Zaporozhan VM, Aryayev ML. HIV-infection and AIDS. Kyiv. Zdorovia. 2004; 636.

Clinical protocol for diagnosis and treatment of opportunistic infections and general symptoms in HIV-infected adults and adolescents. Approved by the Ministry of Health of Ukraine from 13.04.2007; 46.

Markov IS. Treatment and prevention of toxoplasmosis Toksobin drug-specific human immunoglobulin against Toxoplasma. Proceedings of the Conference and Plenum of the infectologists of Ukraine (5-6 May 2004, m. Ternopil). Ternopil. 2004: 268-272.

Pisareva SP, Pusher SN, Litvinov SK. Application of the specific immunoglobulin for Treatment of toxoplasmosis in pregnant women. Zdorovie zhenshchiny. 2004; 3 (19): 1-5.

Kazmirchuk VE, Maltsev DV. Immunoglobulins and immunoglobulin therapy. Kyiv. Phoenix. 2010; 207.

Dykyj BM, Gryzhak IG, Pryshlyak OJ, Kondryn OE, Ostiak RS. Pat. for invention 106190 of Ukraine IPC (2014.01) A61V10/00, G01N33 / 48 (2006.01). Method of diagnosis of toxoplasmosis infection in HIV-infected persons and identifying therapeutic tactics using the diagnostic table. Patent applicant Ivano-Frankivsk National Medical University. № u 2012 12029, appl. 19.10.2012; published on 07.25.2014, Bull. №14.

Toxoplasmosis (Toxoplasma Infection). Center for Disease Control and Prevention. Resources for Health Professionals. Available from:

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.